Tags

Type your tag names separated by a space and hit enter

Clinical perspectives on new antimicrobials: focus on fluoroquinolones.
Clin Infect Dis. 2001 Mar 15; 32 Suppl 1:S64-71.CI

Abstract

Respiratory tract infections are the most common infectious presentation in the community and hospital settings and are a major cause of morbidity and mortality worldwide. Recently, newer fluoroquinolones have been recommended for the treatment of these infections. Among them, moxifloxacin shows improved activity against gram-positive pathogens, has maintained potency against gram-negative organisms, and shows activity against atypical pathogens and anaerobes. Moxifloxacin also has excellent in vitro activity against strains resistant to penicillin, erythromycin, and other fluoroquinolones, such as levofloxacin. Moxifloxacin has demonstrated clinical efficacy rates of 90%-95% in clinical trials in community-acquired pneumonia, acute exacerbations of chronic bronchitis, and acute sinusitis. In these trials, moxifloxacin demonstrated no serious or unexpected adverse effects. Development of resistance appears to be slower for moxifloxacin than for several other fluoroquinolones, making moxifloxacin a good treatment choice. The pharmacodynamics of moxifloxacin support once-daily oral therapy of short duration, providing convenience, compliance, and safety advantages.

Authors+Show Affiliations

Department of Medicine, Divisions of Emergency Medicine and Infectious Diseases, University of California, Los Angeles, CA, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

11249831

Citation

Talan, D A.. "Clinical Perspectives On New Antimicrobials: Focus On Fluoroquinolones." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 32 Suppl 1, 2001, pp. S64-71.
Talan DA. Clinical perspectives on new antimicrobials: focus on fluoroquinolones. Clin Infect Dis. 2001;32 Suppl 1:S64-71.
Talan, D. A. (2001). Clinical perspectives on new antimicrobials: focus on fluoroquinolones. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 32 Suppl 1, S64-71.
Talan DA. Clinical Perspectives On New Antimicrobials: Focus On Fluoroquinolones. Clin Infect Dis. 2001 Mar 15;32 Suppl 1:S64-71. PubMed PMID: 11249831.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical perspectives on new antimicrobials: focus on fluoroquinolones. A1 - Talan,D A, PY - 2001/3/16/pubmed PY - 2001/6/29/medline PY - 2001/3/16/entrez SP - S64 EP - 71 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin Infect Dis VL - 32 Suppl 1 N2 - Respiratory tract infections are the most common infectious presentation in the community and hospital settings and are a major cause of morbidity and mortality worldwide. Recently, newer fluoroquinolones have been recommended for the treatment of these infections. Among them, moxifloxacin shows improved activity against gram-positive pathogens, has maintained potency against gram-negative organisms, and shows activity against atypical pathogens and anaerobes. Moxifloxacin also has excellent in vitro activity against strains resistant to penicillin, erythromycin, and other fluoroquinolones, such as levofloxacin. Moxifloxacin has demonstrated clinical efficacy rates of 90%-95% in clinical trials in community-acquired pneumonia, acute exacerbations of chronic bronchitis, and acute sinusitis. In these trials, moxifloxacin demonstrated no serious or unexpected adverse effects. Development of resistance appears to be slower for moxifloxacin than for several other fluoroquinolones, making moxifloxacin a good treatment choice. The pharmacodynamics of moxifloxacin support once-daily oral therapy of short duration, providing convenience, compliance, and safety advantages. SN - 1058-4838 UR - https://www.unboundmedicine.com/medline/citation/11249831/Clinical_perspectives_on_new_antimicrobials:_focus_on_fluoroquinolones_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1086/319378 DB - PRIME DP - Unbound Medicine ER -